For the second year running, ROVI has obtained the best ranking in the pharmaceutical industry category in the world...
3 min
04 Aug, 2023
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of...
1 min
28 Jul, 2023
ROVI achieved stable total revenue of 381.0 million euros in the first post-pandemic half year
4 min
26 Jul, 2023
ROVI reached 201.9 million euros of revenue in the first post-pandemic quarter
3 min
10 May, 2023
The objective of the new three-monthly formulation is to reach bioequivalence in the plasma levels of letrozole in...
6 min
25 Apr, 2023
The objective is to help improve society’s mental health and take advantage of the opportunities the new technologies...
3 min
12 Apr, 2023
The group is collaborating with ReTree to recover an area of the Sierra del Rincón through reforestation with native...
3 min
27 Mar, 2023
ROVI joins BioSim to strengthen initiatives that promote greater access to and knowledge about biosimilar medicines.
3 min
21 Mar, 2023
ROVI reports operating revenue growth of 26% and EBITDA growth of 37%
3 min
21 Feb, 2023